Lv21
180 积分 2024-12-10 加入
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
12天前
已完结
As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss
17天前
已完结
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
23天前
已关闭
Lipoprotein(a) - From Biomarker to Therapy: A Review for the Clinician
24天前
已完结
Does Receptor Balance Matter? - Comparing the Efficacies of the Dual Amylin and Calcitonin Receptor Agonists Cagrilintide and KBP-336 on Metabolic Parameters in Preclinical Models. Biomed Pharmacother
2个月前
已完结
The unexpected role of GIP in transforming obesity treatment
2个月前
已完结
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity
2个月前
已完结
The unexpected role of GIP in transforming obesity treatment
2个月前
已完结
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
2个月前
已完结
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight
2个月前
已完结
皖公网安备34019202002308
